International Scholarly Research Notices

International Scholarly Research Notices / 2013 / Article

Research Article | Open Access

Volume 2013 |Article ID 203941 | https://doi.org/10.1155/2013/203941

Yingchang Lu, Sinae Kane, Haoyan Chen, Argentina Leon, Ethan Levin, Tien Nguyen, Maya Debbaneh, Jillian W. Millsop, Rishu Gupta, Monica Huynh, Daniel Butler, Kelly Cordoro, Wilson Liao, "The Role of 39 Psoriasis Risk Variants on Age of Psoriasis Onset", International Scholarly Research Notices, vol. 2013, Article ID 203941, 4 pages, 2013. https://doi.org/10.1155/2013/203941

The Role of 39 Psoriasis Risk Variants on Age of Psoriasis Onset

Academic Editor: C. Ferrándiz
Received16 Jul 2013
Accepted29 Aug 2013
Published23 Sep 2013

Abstract

Recent genome-wide association studies (GWAS) have identified multiple genetic risk factors for psoriasis, but data on their association with age of onset have been marginally explored. The goal of this study was to evaluate known risk alleles of psoriasis for association with age of psoriasis onset in three well-defined case-only cohorts totaling 1,498 psoriasis patients. We selected 39 genetic variants from psoriasis GWAS and tested these variants for association with age of psoriasis onset in a meta-analysis. We found that rs10484554 and rs12191877 near HLA-C and rs17716942 near IFIH1 were associated with age of psoriasis onset with false discovery rate < 0.05. The association between rs17716942 and age of onset was not replicated in a fourth independent cohort of 489 patients ( ). The imputed HLA-C*06:02 allele demonstrated a much stronger association with age of psoriasis onset than rs10484554 and rs12191877. We conclude that despite the discovery of numerous psoriasis risk alleles, HLA-C*06:02 still plays the most important role in determining the age of onset of psoriasis. Larger studies are needed to evaluate the contribution of other risk alleles, including IFIH1, to age of psoriasis onset.

1. Introduction

Psoriasis is an inflammatory, immune-mediated disorder of the skin, joints, and nails with an estimated prevalence of 2-3% of the population. Henseler and Christophers divided psoriasis into two subtypes. Type I psoriasis manifests before age 40 with peak onset at 16–22 years, and Type II psoriasis begins after age 40 with peak onset at 57–60 years [1]. Type I and II psoriasis have been shown to differ clinically in their severity, relapse frequency, and family history [1, 2]. The clinical differences in Type I and Type II psoriasis are paralleled by genetic differences. Type I psoriasis has a stronger genetic basis as a greater proportion of patients had a family history of psoriasis, and has stronger HLA-C*06 associations; however, Type II psoriasis is negative in family history, and is not associated with HLA-C*06 [1, 3, 4]. Over the past few years, over 36 novel psoriasis loci have been identified through genome-wide association studies (GWAS) [513]. However, it is not known to what degree these susceptibility alleles influence the age of onset of psoriasis. Here, we examined 39 of these genetic variants in 3 cohorts of psoriasis cases to ascertain whether any of these loci were preferentially associated with the age of psoriasis onset.

2. Materials and Methods

The SNPs were selected from psoriasis GWAS conducted in Caucasian populations (published before December 2012; see Supplementary Table 1 available online at http://dx.doi.org/10.1155/2013/203941), taking into account the potential molecular mechanisms underlying the pathogenesis of psoriasis [14]. We evaluated 39 SNPs for association with age of psoriasis onset in two psoriasis GWAS case cohorts; 13 of those SNPs were genotyped by Illumina GoldenGate assay in a third cohort of 418 cases at the University of California San Francisco (UCSF) (Table 1). rs17716942 in IFIH1 was genotyped in a fourth independent cohort of 489 National Psoriasis Foundation (NPF) cases using the Applied Biosystems Taqman genotyping assay. Age of onset of psoriasis was determined by patient self-report and by the treating dermatologist. The two GWAS cohorts consisted of the Genetic Association Information Network (GAIN) cohort including 898 cases [7] and the Washington University/University of California San Francisco cohort (WashU/UCSF) including 182 cases [6]. IMPUTE2 [15] was used to impute the ungenotyped SNPs in these two case cohorts by using phase 3 HapMap and 1000 Genomes pilot project CEU haplotypes as a reference. Since the distributions of the age onset of psoriasis in our four independent case cohorts were not bimodal but positively skewed (Supplementary   1–4), a square-root transformed age onset was used in the analysis. The linear regression quantitative trait test in SNPTEST was used to associate the imputed dosage for each SNP with the age onset of psoriasis separately in GAIN and WashU/UCSF cohorts with the adjustment of gender. Only imputed SNPs with relatively high confidence (PROPER_Info > 0.5) were analyzed [16]. The association results from the GAIN cohort, WashU/UCSF cohort, and UCSF cohort were then combined by meta-analysis using inverse-variance method based on a fixed-effect model. The false discovery rate method was used to correct for multiple testing (FDR_ ).


Nearby geneRs_idRisk allele of psoriasis/effect allele of age onset _GAIN _WashU/UCSF _UCSFBeta for effect allele of age onset _heterogeneityMeta- valueFDR_ value _NPF

HLA-CHLA-Cw6 0.0005 −0.6180.73
HLA-Crs10484554T/T 0.01670.000016−0.3800.39 <0.0001
HLA-Crs12191877T/T 0.01740.000018−0.3720.39 <0.0001
IFIH1rs17716942T/T0.00140.06680.464−0.2010.090.0020.0280.94
HLA-Crs13191343T/T0.00250.9000−1−0.1880.220.0060.054
LCE3B-LCE3Crs4112788G/G0.00740.82990.8248−0.0990.370.0210.166
FBXL19rs10782001G/A0.03660.9682−1−0.0850.370.0590.37
SDC4rs1008953C/C0.18760.1478−10.1040.470.0690.37
FBXL19rs12924903A/G0.05740.8552−1−0.0740.340.0990.37
TRAF3IP2rs240993T/C0.06590.9254−1−0.0770.400.1020.37
IL23Rrs11209026G/G0.30620.62840.1364−0.1630.650.1040.37
IL12Brs2546890A/G0.06300.8726−10.0740.360.1040.37
IL12Brs12188300T/T0.05620.5824−1−0.1100.200.1260.409
IL12Brs6887695G/G0.12300.96130.73260.0650.790.1550.466
IL23Rrs1004819—/A0.36570.3654−1−0.0590.660.2300.641
IL12Brs953861G/A0.17770.8474−10.0610.450.2580.672
RPS26rs12580100A/G−10.3151−10.164−10.3150.768
TRAF3IP2rs13210247G/G0.63190.0106−1−0.0520.010.4800.985
IL28RArs4649203A/A0.44290.9925−1−0.0390.730.4930.985
NFKBIArs8016947G/G0.24240.1851−1−0.0260.090.5720.985
TRAF3IP2rs33980500T/T0.51990.0131−1−0.0450.010.5730.985
IL12Brs3212227T/G0.70460.73320.87640.0300.990.6060.985
RNF114rs2235617C/G0.99220.99540.2331−0.0190.550.6400.985
IL12Brs3213094C/T0.75990.72160.87640.0260.980.6440.985
RELrs702873C/T0.54960.8308−1−0.0190.650.6580.985
TRAF3IP2rs458017C/C0.29330.0073−1−0.0340.0040.6620.985
IL23Ars2066808A/G0.36000.22950.05120.0400.050.6800.985
TNIP1rs1024995C/C0.72060.1018−1−0.0270.100.6900.985
TRAF3IP2rs13190932A/A0.44340.0415−1−0.0210.030.7910.985
Noners6809854G/G0.63100.0975−10.0140.090.7940.985
TRAF3IP2rs13196377A/G0.39150.0396−10.0190.030.8120.985
NOS2rs4795067G/G0.78160.2546−1−0.0090.250.8440.985
RNF114rs495337G/A0.84240.9978−10.0080.930.8560.985
IL13rs20541G/G0.79180.89790.9620.0100.970.8570.985
NFKBIArs12586317T/C0.74870.7428−10.0080.670.8780.985
ERAP1rs27524A/G0.82400.8969−10.0070.830.8840.985
TYK2rs280519A/G0.58670.2155−10.0040.180.9390.992
TNIP1rs17728338A/A0.78050.60410.7386−0.0050.800.9420.992
TNFAIP3rs610604G/T0.89970.91780.7863−0.0020.950.9670.992
TYK2rs12720356A/C0.72750.5667−10.0010.500.9920.992

FDR_ : false discovery rate adjusted value based on 39 selected SNPs. In total, 898, 182, 418, and 489 psoriasis cases were included in the GAIN, WashU/UCSF, UCSF, and NPF case cohorts, respectively; for certain SNPs that were imputed with low confidence (proper_info < 0.5 for rs12580100) in GAIN cohort or were not genotyped in UCSF case cohort, their information (denoted as = “−1”) was not included in the corresponding meta-analysis; Cochran's statistic was used to examine the heterogeneity.

3. Results

We used linear regression to evaluate the association of 39 psoriasis genetic loci with age of psoriasis onset in a combined sample of 1,498 cases. These loci were identified by previous psoriasis genome-wide association studies and include variants within or near the HLA locus, IL23R, IL12B, TNIP1, TNFAIP3, IL23A, IL13, TRAF3IP2, LCE3B/3C, RNF114, IFIH1, ERAP1, REL, TYK2, NFKBIA, NOS2, IL28RA, SDC4, FBXL19, and RPS26. We found that rs10484554 and rs12191877 near HLA-C and rs17716942 near IFIH1 were associated with age onset of psoriasis with FDR_q value < 0.05. As expected, the alleles associated with increased risk of psoriasis were also associated with younger age of onset of psoriasis (Table 1). However, the association between rs17716942 and age of psoriasis onset was not replicated in the NPF cases ( and for the T allele, Table 1). Since the top two SNPs associated with age of onset were located near the HLA-C locus, we further imputed HLA-C*06:02 in GAIN, WashU/UCSF, and UCSF case cohorts as previously described [17]. HLA-C*06:02 was more strongly associated with age of onset than the two individual HLA-C SNPs (Table 1). Our linear regression model revealed that psoriasis patients with two copies of HLA-C*06:02 developed psoriasis on average at age 15, psoriasis patients with one copy of HLA-C*06:02 developed psoriasis at age 21, and psoriasis patients with zero copies of HLA-C*06:02 developed psoriasis at age 27. Thus, each additional copy of HLA-C*06:02 reduced the onset of psoriasis by 6 years.

4. Discussion

In this study we found that among the many psoriasis loci discovered by GWAS, only the HLA-C locus showed robust evidence of playing a role in earlier psoriasis onset. The HLA-C*06:02 allele had a stronger effect on age of onset than individual HLA-C SNPs, and this allele was highly significant in each of the three individual cohorts studied ( ). In our study population, psoriasis patients with two copies of HLA-C*06:02 developed psoriasis nearly 12 years earlier than those without HLA-C*06:02. This is likely to underestimate the true effect of HLA-C*06:02 because our study population contained relatively more type I psoriasis (onset < age 40) than type II psoriasis (onset > age 40) (Supplementary –4), where it has been shown that C*06:02 is more common in type I psoriasis compared to type II psoriasis [1, 3, 4]. The SNP rs17716942 in the innate antiviral gene IFIH1 was also significant in the meta-analysis ( , FDR < 0.05). IFIH1 encodes a cytoplasmic helicase that acts as a sensor for double-stranded RNA. However, this SNP was not significantly associated with age of onset when examined in an independent cohort, thus further examination of this gene in additional cohorts is warranted.

Genetic variations in ERAP1, IL23R, and LCE3B/LCE3C have recently been associated with pediatric-onset psoriasis (onset < age 18) in a small study [18]. However, in that study the same variants were also shown to be associated with adult-onset psoriasis, suggesting, they may not be specific to pediatric-onset psoriasis. In our study, LCE3B/LCE3C was significantly associated with age of onset in the GAIN cohort ( ), but not in the meta-analysis (FDR = 0.17). We did not observe any evidence for association of ERAP1 or IL23R in our data.

Considering that HLA-C*06:02 has a much larger effect size (odds ratio > 3.0) on the risk of developing psoriasis compared to the other psoriasis risk alleles (odds ratios < 2.0), it is possible that some of these other risk alleles have a smaller influence on age of onset that would only be detected in a study of larger sample size. There could also be a cumulative additive effect of psoriasis risk alleles on age of onset. Indeed, it has previously been shown that a genetic risk score that combines the genetic burden of the top ten psoriasis genes is significantly higher in patients who develop psoriasis before age 30 compared to those who develop psoriasis after age 30 [19].

In summary, in a large dataset of 1,498 cases we have examined 39 psoriasis variants for their association with age of psoriasis onset. Only the HLA-C locus demonstrated robust evidence of association with age of onset, with HLA-C*06:02 having the strongest effect. In the meta-analysis a variant in IFIH1 was also found to be significant, however this SNP was not replicated in an independent cohort. Further studies are needed to clarify the role of genetic variants on the age at which psoriasis manifests.

Authors’ Contribution

Yingchang Lu and Sinae Kane contributed equally to this work.

Acknowledgments

The GAIN dataset used for the analyses described in this paper was obtained from the database of Genotypes and Phenotypes (dbGaP) found at http://www.ncbi.nlm.nih.gov/gap/ through dbGaP accession number phs000019.v1.p1. Samples and associated phenotype data for the Collaborative Association Study of Psoriasis were provided by Drs. James T. Elder (University of Michigan, Ann Arbor, MI), Gerald G. Krueger (University of Utah, Salt Lake City, UT), Anne Bowcock (Washington University, St. Louis, MO), and Gonçalo R. Abecasis (University of Michigan, Ann Arbor, MI). This project has been funded in part by federal funds from the National Institutes of Health under Award 5K08AR057763 to Wilson Liao.

Supplementary Materials

The Supplementary Material contains the following: a list of single nucleotide polymorphisms (SNPs) associated with psoriasis that were examined in this study (Supplementary Table 1), a histogram showing the distribution of age of psoriasis onset in the GAIN cohort (Supplementary Figure 1), a histogram showing the distribution of age of psoriasis onset in the Washington University and UCSF cohort (Supplementary Figure 2), a histogram showing the distribution of age of psoriasis onset in the UCSF cohort (Supplementary Figure 3), and a histogram showing the distribution of age of psoriasis onset in the National Psoriasis Foundation cohort (Supplementary Figure 4).

  1. Supplementary Material

References

  1. T. Henseler and E. Christophers, “Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris,” Journal of the American Academy of Dermatology, vol. 13, no. 3, pp. 450–456, 1985. View at: Google Scholar
  2. C. Ferrándiz, R. M. Pujol, V. García-Patos, X. Bordas, and J. A. Smandía, “Psoriasis of early and late onset: a clinical and epidemiologic study from Spain,” Journal of the American Academy of Dermatology, vol. 46, no. 6, pp. 867–873, 2002. View at: Google Scholar
  3. M. H. Allen, H. Ameen, C. Veal et al., “The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis,” Journal of Investigative Dermatology, vol. 124, no. 1, pp. 103–106, 2005. View at: Publisher Site | Google Scholar
  4. J. E. Guojónsson, A. Kárason, A. A. Antonsdóttir et al., “HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features,” Journal of Investigative Dermatology, vol. 118, no. 2, pp. 362–365, 2002. View at: Publisher Site | Google Scholar
  5. F. Capon, M.-J. Bijlmakers, N. Wolf et al., “Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene,” Human Molecular Genetics, vol. 17, no. 13, pp. 1938–1945, 2008. View at: Publisher Site | Google Scholar
  6. Y. Liu, C. Helms, W. Liao et al., “A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci,” PLoS Genetics, vol. 4, no. 3, Article ID e1000041, 2008. View at: Publisher Site | Google Scholar
  7. R. P. Nair, K. C. Duffin, C. Helms et al., “Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways,” Nature Genetics, vol. 41, no. 2, pp. 199–204, 2009. View at: Google Scholar
  8. P. E. Stuart, R. P. Nair, E. Ellinghaus et al., “Genome-wide association analysis identifies three psoriasis susceptibility loci,” Nature Genetics, vol. 42, no. 11, pp. 1000–1004, 2010. View at: Google Scholar
  9. E. ELinghaus, D. ELinghaus, P. E. Stuart et al., “Genome-wide asociation study identifies a psoriasis susceptibility locus at TRAF3IP2,” Nature Genetics, vol. 42, no. 11, pp. 991–995, 2010. View at: Publisher Site | Google Scholar
  10. U. Hüffmeier, S. Uebe, A. B. Ekici et al., “Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis,” Nature Genetics, vol. 42, no. 11, pp. 996–999, 2010. View at: Google Scholar
  11. A. Strange, F. Capon, C. C. Spencer et al., “A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1,” Nature Genetics, vol. 42, no. 11, pp. 985–990, 2010. View at: Google Scholar
  12. R. de Cid, E. Riveira-Munoz, P. L. J. M. Zeeuwen et al., “Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis,” Nature Genetics, vol. 41, no. 2, pp. 211–215, 2009. View at: Publisher Site | Google Scholar
  13. L. C. Tsoi, S. L. Spain, J. Knight et al., “Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity,” Nature Genetics, vol. 44, no. 12, pp. 1341–1348, 2012. View at: Google Scholar
  14. J. T. Elder, A. T. Bruce, J. E. Gudjonsson et al., “Molecular dissection of psoriasis: integrating genetics and biology,” Journal of Investigative Dermatology, vol. 130, no. 5, pp. 1213–1226, 2010. View at: Google Scholar
  15. B. N. Howie, P. Donnelly, and J. Marchini, “A flexible and accurate genotype imputation method for the next generation of genome-wide association studies,” PLoS Genetics, vol. 5, no. 6, Article ID e1000529, 2009. View at: Publisher Site | Google Scholar
  16. P. I. de Bakker, M. A. R. Ferreira, X. Jia, B. M. Neale, S. Raychaudhuri, and B. F. Voight, “Practical aspects of imputation-driven meta-analysis of genome-wide association studies,” Human Molecular Genetics, vol. 17, no. R2, pp. R122–R128, 2008. View at: Publisher Site | Google Scholar
  17. H. Chen, G. Hayashi, O. Y. Lai et al., “Psoriasis patients are enriched for genetic variants that protect against HIV-1 disease,” PLoS Genetics, vol. 8, no. 2, Article ID e1002514, 2012. View at: Google Scholar
  18. J. G. Bergboer, A. M. Oostveen, M. E. de Jager et al., “Paediatric-onset psoriasis is associated with ERAP1 and IL23R loci, LCE3C_LCE3B deletion and HLA-C*06,” British Journal of Dermatology, vol. 167, no. 4, pp. 922–925, 2012. View at: Google Scholar
  19. H. Chen, A. Poon, C. Yeung et al., “A genetic risk score combining ten psoriasis risk loci improves disease prediction,” PLoS ONE, vol. 6, no. 4, Article ID e19454, 2011. View at: Publisher Site | Google Scholar

Copyright © 2013 Yingchang Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

1597 Views | 637 Downloads | 4 Citations
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.